The drug, called amycretin and codenamed NN9487, is a dual agonist that targets both GLP-1 and amylin and is being developed in both oral and subcutaneous injection formulations. The oral form has ...

and also has early-stage results for a next-generation candidate called amycretin. Pfizer recently selected a once-daily formulation of danuglipron as its candidate for phase 3 testing ...